These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. Konstance R; Tcheng JE; Wightman MB; Kelly LP; Moore A; Harrison JK; Sketch MH J Interv Cardiol; 2004 Apr; 17(2):65-70. PubMed ID: 15104767 [TBL] [Abstract][Full Text] [Related]
67. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting. Wholey MH; Wholey MH; Eles G; Toursakissian B; Bailey S; Jarmolowski C; Tan WA J Endovasc Ther; 2003 Feb; 10(1):33-41. PubMed ID: 12751927 [TBL] [Abstract][Full Text] [Related]
68. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban. King S; Short M; Harmon C Vascul Pharmacol; 2016 Mar; 78():10-6. PubMed ID: 26187354 [TBL] [Abstract][Full Text] [Related]
69. Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis. Brinjikji W; Morales-Valero SF; Murad MH; Cloft HJ; Kallmes DF AJNR Am J Neuroradiol; 2015 Jan; 36(1):121-5. PubMed ID: 25082819 [TBL] [Abstract][Full Text] [Related]
70. [New thrombocyte aggregation inhibitor in therapy of unstable angina]. Hamm C Z Kardiol; 2000 Nov; 89(11):1053-6. PubMed ID: 11149273 [TBL] [Abstract][Full Text] [Related]
71. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors. Dunn A Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344 [No Abstract] [Full Text] [Related]
73. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria. Kini AS; Reich D; Mitre CA; Sharma SK Am J Cardiol; 2001 Dec; 88(11):1287-90. PubMed ID: 11728356 [No Abstract] [Full Text] [Related]
75. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. Mandava P; Thiagarajan P; Kent TA Drugs; 2008; 68(8):1019-28. PubMed ID: 18484795 [TBL] [Abstract][Full Text] [Related]
76. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Kondo K; Umemura K Clin Pharmacokinet; 2002; 41(3):187-95. PubMed ID: 11929319 [TBL] [Abstract][Full Text] [Related]
77. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. Tcheng JE Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575 [No Abstract] [Full Text] [Related]
78. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Huxtable LM; Tafreshi MJ; Rakkar AN Am J Cardiol; 2006 Feb; 97(3):426-9. PubMed ID: 16442410 [TBL] [Abstract][Full Text] [Related]
79. Glycoprotein IIb/IIIa inhibitors. Stevens M Intensive Crit Care Nurs; 2002 Feb; 18(1):64-6. PubMed ID: 12008879 [TBL] [Abstract][Full Text] [Related]
80. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes. Kereiakes DJ; McDonald M; Broderick T; Roth EM; Whang DD; Martin LH; Howard WL; Schneider J; Shimshak T; Abbottsmith CW Am Heart J; 2000 Feb; 139(2 Pt 2):S53-60. PubMed ID: 10650317 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]